Codonolactone (CLT). It inhibited the expression of acquired EMT’s mesenchymal markers such as N-cadherin and vimentin in a dose-dependent manner in in vivo and in vitro experiments in breast cancer. This evidence concerns the gene CDH2 and breast cancer.